Table 3. Drug‐diagnostic combinations that have obtained FDA approval based on efficacy data from small phase I/II trials.

^aNew indication.

^bPatients with unresectable or metastatic, MSI‐H, or dMMR solid tumors.

^cPatients with solid tumors with a neurotrophic receptor tyrosine kinase (NRTK) gene fusion.

The figures in the last column are the number of patients for whom efficacy data were available at the time of drug approval [41].

Abbreviations: dMMR, mismatch repair deficient; MSI‐H, microsatellite instability‐high.